Download PDF
Thromb Haemost 2003; 90(06): 1094-1099
DOI: 10.1160/TH03-03-0134
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Hemostatic risk factors in ischemic stroke

Franziska Demarmels Biasiutti
1   Central Hematology Laboratory, Inselspital, University of Bern, Switzerland
,
Daniela Berger
1   Central Hematology Laboratory, Inselspital, University of Bern, Switzerland
,
Heinrich P. Mattle
2   Department of Neurology, Inselspital, University of Bern, Switzerland
,
Bernhard Lämmle
1   Central Hematology Laboratory, Inselspital, University of Bern, Switzerland
,
Walter A. Wuillemin
1   Central Hematology Laboratory, Inselspital, University of Bern, Switzerland
3   Division of Hematology, Department of Internal Medicine, Kantonsspital Lucerne, Switzerland
› Author Affiliations
Further Information

Publication History

Received 06 March 2003

Accepted after revision 05 August 2003

Publication Date:
05 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

The role played by hemostasis in the pathogenesis of ischemic stroke is still controversial. In the present study, we looked for a possible association of ischemic stroke and high clotting activity of factor II (FII:C), factor V (FV:C), factor VII (FVII:C), factor X (FX:C) and fibrinogen. We investigated 157 non-anti-coagulated patients (86 males, 71 females; median age 41 y, range 16-73 ), who had survived ischemic stroke for at least 2 months, and 193 healthy controls with similar age and sex distribution (104 males, 89 females; median age 39 y, range 19-74). Patients showed significantly higher body mass index, as well as significantly higher prevalence of arterial hypertension, smoking and hyperlipidemia. FV:C (p = 0.05), FX:C (p = 0.04) and fibrinogen (p = 0.05) were higher in patients as compared to controls. In a univariate risk analysis FX:C and FV:C were associated with the relative risk for ischemic stroke showing an odds ratio (OR) of up to 2.8 (95% CI: 1.05-7.6) and 3.4 (95%CI: 1.4-7.9), respectively, for levels above 130%. In a multivariate analysis using a logistic regression model including age, sex, arterial hypertension, smoking habit, diabetes, hyperlipidemia, BMI and the coagulation factors, FV:C was still found to significantly (p=0.03) add to the risk of ischemic stroke. An increase of factor FV:C by 10% was associated with an increase in the relative risk of 19% (95% CI.: 2%-38%). In conclusion, we found a high plasma level of FV:C to be a prevalent (FV:C > 130% in 20/157 patients) and independent risk factor for ischemic stroke.

Keywords

Ischemic stroke - risk factors - coagulation - factor V
 

  • References

  • 1 WHO. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke-1989: Recommendations on stroke prevention, diagnosis, and therapy. Stroke 1989; 20: 1407-31.
    CrossrefPubMedGoogle Scholar
  • 2 Sacco RL, Benjamin EJ, Broderick JP. et al. AHA Conference Proceedings: Risk Factors. Stroke 1997; 28: 1507-17.
    CrossrefPubMedGoogle Scholar
  • 3 Wolf PA. Prevention of stroke. Lancet 1998; III suppl 15-18.
    PubMedGoogle Scholar
  • 4 Shinton R, Beevers G. Meta-analysis of relation between smoking and stroke. Br Med J 1989; 25: 789-94.
    PubMedGoogle Scholar
  • 5 Wannamethee SG, Perry IJ, Shaper G. Nonfasting serum glucose and insulin concentrations and the risk of stroke. Stroke 1999; 30: 1780-6.
    CrossrefPubMedGoogle Scholar
  • 6 Iso H, Jacobs Jr DR, Wentworth D. et al. Serum cholesterol levels and six-year mortality from stroke in 350’977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320: 904-10.
    CrossrefPubMedGoogle Scholar
  • 7 Tegos TJ, Kalodiki E, Daskalopoulou SS. et al. Stroke: Epidemiology, clinical picture, and risk factors. Angiology 2000; 51: 793-808.
    CrossrefPubMedGoogle Scholar
  • 8 Catto AJ, Grant PJ. Risk factors for cerebro-vascular disease and the role of coagulation and fibrinolysis. Blood Coagul Fibrinolysis 1995; 6: 497-510.
    CrossrefPubMedGoogle Scholar
  • 9 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K. et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 23: 501-5.
    PubMedGoogle Scholar
  • 10 Kannel WB, Wolf PA, Castelli WP. et al. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA 1987; 258: 1183-6.
    CrossrefPubMedGoogle Scholar
  • 11 Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Int Med 1993; 118: 956-63.
    CrossrefPubMedGoogle Scholar
  • 12 Kario K, Matsuo M, Miyata T. Are there any associations among coagulation factor VII gene polymorphism, plasma activated factor VII levels, and cerebrovascular disease ?. Circulation 2000; 101: E48
    CrossrefPubMedGoogle Scholar
  • 13 Folsom AR, Rosamond WD, Shahar E. et al. for the ARIC Study investigators. Prospective study of markers of hemostatic function with risk of ischemic stroke. Circulation 1999; 100: 736-42.
    CrossrefPubMedGoogle Scholar
  • 14 Qizilbash N, Duffy S, Prentice CR. et al. Von Willebrand factor and risk of ischemic stroke. Neurology 1997; 49: 1552-56.
    CrossrefPubMedGoogle Scholar
  • 15 Smith FB, Lee AJ, Fowkes FGR. et al. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-5.
    CrossrefPubMedGoogle Scholar
  • 16 Macko RF, Kittner SJ, Epstein A. et al. Elevated tissue plasminogen activator antigen and stroke risk. The stroke prevention in young women study. Stroke 1999; 30: 7-11.
    CrossrefPubMedGoogle Scholar
  • 17 De Stefano V, Chiusolo P, Paciaroni K. et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998; 91: 3562-5.
    PubMedGoogle Scholar
  • 18 Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999; 99: 999-1004.
    CrossrefPubMedGoogle Scholar
  • 19 Szolnoki Z, Somogyvári F, Szabó M. et al. A clustering of unfavourable commmon genetic mutations in stroke cases. Acta Neurol Scand 2000; 102: 124-8.
    CrossrefPubMedGoogle Scholar
  • 20 Wu AH, Tsongalis GJ. Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. Am J Cardiol 2001; 87: 1361-6.
    CrossrefPubMedGoogle Scholar
  • 21 Catto A, Carter A, Ireland H. et al. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol 1995; 15: 783-5.
    CrossrefPubMedGoogle Scholar
  • 22 Ridker PM, Hennekens CH, Lindpaintner K. et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
    CrossrefPubMedGoogle Scholar
  • 23 Voetsch B, Damasceno BP, Camargo ECS. et al. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost 2000; 83: 229-33.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Sacco RL, Owen J, Mohr JP. et al. Free protein S deficiency: a possible association with cerebrovascular occlusion. Stroke 1989; 20: 1657-61.
    CrossrefPubMedGoogle Scholar
  • 25 D’Amico D, Moschiano F, Leone M. et al. Genetic abnormalities of the protein C system: shared risk factors in young adults with migraine with aura and with ischemic stroke. Cephalgia 1998; 18: 618-21.
    CrossrefPubMedGoogle Scholar
  • 26 Boushey CJ, Beresford SA, Omenn GS. et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
    CrossrefPubMedGoogle Scholar
  • 27 Madonna P, de Stefano V, Coppola A. et al. Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke 2002; 33: 51-56.
    CrossrefPubMedGoogle Scholar
  • 28 Vasse M, Guegan-Massardier E, Borg JY. et al. Frequency of protein Z deficiency in patients with ischemic stroke. Lancet 2001; 357: 933-4.
    CrossrefPubMedGoogle Scholar
  • 29 Kobelt K, Demarmels Biasiutti F, Mattle HP. et al. Protein Z in ischemic stroke. Br J Haematol 2001; 114: 169-73.
    CrossrefPubMedGoogle Scholar
  • 30 Tuhrim S, Rand JH, Wu X. et al. Antiphosphatidyl serine antibodies are independently associated with ischemic stroke. Neurology 1999; 53: 1523-7.
    CrossrefPubMedGoogle Scholar
  • 31 Brey RL, Hart RG, Sherman DG. et al. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990; 40: 1190-6.
    CrossrefPubMedGoogle Scholar
  • 32 Adams HP, Bendixen BH, Kappelle LJ. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 1993; 24: 35-41.
    CrossrefPubMedGoogle Scholar
  • 33 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46.
    CrossrefPubMedGoogle Scholar
  • 34 Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. Br Med J 1995; 310: 170
    CrossrefPubMedGoogle Scholar
  • 35 Hankey GJ, Eikelboom JW, van Bockxmeer FM. et al. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 2001; 32: 1793-9.
    CrossrefPubMedGoogle Scholar
  • 36 Redondo M, Watzke HH, Stucki B. et al. Coagulation factors II, V, VII, and X, pro-thrombin gene 20210G A transition, and factor V Leiden in coronary artery disease. High factor V clotting activity is an independent risk factor for myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 1020-5.
    CrossrefPubMedGoogle Scholar